Kazem Rahimi, MD
University of Oxford, Oxford, England (UK)
Kazem Rahimi is a Professor of Cardiovascular Medicine and Population Health, at the University of Oxford and a consultant cardiologist at the Oxford University Hospitals NHS Trust. His research interests include hypertension, heart failure, multimorbidity and cardiovascular risk management, using a variety of methodologies such as individual-patient meta-analysis, large-scale decentralised clinical trials, and digital health technologies.
Kazem leads the Deep Medicine programme at the Nuffield Department of Women’s and Reproductive Health with a major interest in application of machine learning approaches to electronic health records. He also leads the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC), which is an international collaboration of all the major trials of blood pressure lowering drugs. He is the Director of the Martin School programme on Informal Cities
Matthew Lee, MD
University of Glasgow, Glasgow, Scotland (UK)
Dr Matthew Lee trained in medicine at the University of Edinburgh (MBChB 2010). He undertook general professional training in medicine in South East Scotland (2010-2012) and the West of Scotland (2012-2014). He is a Cardiology Specialist Registrar in the West of Scotland (from 2014) and Clinical Lecturer at the School of Cardiovascular and Metabolic Health at the University of Glasgow. His interests include diabetes, pharmacotherapy (SGLT2i, GLP-1RA, myosin inhibitors), heart failure, cardiomyopathies, obesity/weight loss, clinical trials, meta-analysis, systematic review and multi-modality imaging (CMR, renal MRI, TTE, lung ultrasound). He was awarded the Bellahouston Medal for his PhD at the University of Glasgow (2022), based on the SUGAR-DM-HF trial. He is currently a CardioVascular Clinical Trialists (CVCT) Future Trialists Fellow. He serves on trial steering committees (SEQUOIA-HCM) and clinical event committees (FINEARTS-HF, REVIVED-BCIS2, CABG-ACS). He is a co-grant holder for BIOPEF, EMPRESS-MI, DAPA-RESIST and SUGAR-DM-HF. He is/was a co-/sub-investigator for STEP-HFpEF, SOUL, Dapa-HF, PARADISE-MI, PARAGON-HF, IRONMAN, FAMOUS-NSTEMI, CABG-ACS and the Air Pollution Facemask Study.
Jennifer Green, MD
Duke University, Durham, NC (US)
Dr. Jennifer Green is a professor of medicine in the division of endocrinology, metabolism, and nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. Her research has focused upon strategies to treat diabetes mellitus and reduce the risk of cardiovascular, kidney and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as US coordinating center PI and US national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease.
Dr. Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. She is now a member of the ADA-EASD writing group which recently revised a joint consensus statement on the management of hyperglycemia in type 2 diabetes.
Peter Rossing, MD, DMSc
Steno Diabetes Center, University of Copenhagen, Copenhagen, Denmark
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center Copenhagen research team dedicated to the research of micro-and macrovascular complications of diabetes.
Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
He was coordinator of the EU FP7 project PRIORITY demonstrating that urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy, the STENO1 and member of several trial steering groups and guideline committees.
He has co-authored >650 papers and his h-index is 86. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA and the Hormon Medal from European Society of Endocrinology. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry
Stefan Mutter, PHD
Folkhälsan Research Center, Helsinki, Finland
Dr Stefan Mutter works as a data scientist for the FinnDiane study looking after the world largest cohort of individuals living with type 1 diabetes at the Folkhälsan Research Center in Helsinki, Finland. He graduated in Computer Science in 2004 from the University of Freiburg, Germany and received his PhD in Artificial Intelligence from the University of Waikato in Hamilton, New Zealand in 2011. Prior to his work at the FinnDiane study group, he was an EMBL Australia Post-doctoral fellow in biomedical informatics at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia. He is interested in identifying individuals at risk of disease and especially of complications of type 1 diabetes in a better and earlier way and therefore contributing towards improving patients’ outcomes.
Joshua A. Beckman, MD, MSc
UT Southwestern Medical Center, Dallas, TX (US)
Joshua A. Beckman, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, where he holds the Gayle and Paul Stoffel Distinguished Chair in Cardiology. He specializes in vascular and cardiovascular medicine and serves as the department’s Director of Vascular Medicine.
Dr. Beckman earned his medical degree at the New York University School of Medicine and completed his residency in internal medicine at Columbia Presbyterian Hospital, where he served as Chief Resident. He received advanced training in cardiovascular medicine and vascular medicine through fellowships at Brigham and Women's Hospital. He also holds a bachelor’s degree in American political history from the University of Pennsylvania and a master’s degree in epidemiology from the Harvard School of Public Health.He is actively involved in several professional organizations, including the Society for Vascular Medicine, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Association of University Cardiologists. In addition, he is Chair of the AHA/ACC Joint Committee on Guidelines.
Dr. Beckman’s clinical and translational research focuses on the mechanisms that cause vascular dysfunction, susceptibility to atherosclerosis, and functional limitations in peripheral artery disease. His research has received funding from federal, foundation, and industry sources, and he is a co-inventor of a pending patent. His work has been published in numerous medical journals.
He is an associate editor of Circulation, a member of the editorial boards of Journal of the American College of Cardiology and Vascular Medicine, and a reviewer for many other scholarly journals. He is also an editor of the textbook Vascular Medicine: A Companion to Braunwald’s Heart Disease.
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Icahn School of Medicine at Mount Sinai, New York City, NY (USA)
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI, is the Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York City.
He is working on his Executive MBA from Oxford. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He has been listed in Best Doctors in America from 2005 to 2020. He received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, NLA’s Honorary Lifetime Membership Award in 2021, and SCAI’s Master designation in 2022.
Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2023. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-Editors of Braunwald’s Heart Disease. He is the Editor of the Journal of Invasive Cardiology. He had served as Senior Associate Editor for News and Clinical Trials for ACC.org and as a Trustee of the ACC.
Vanita R. Aroda, MD
Brigham and Women's Hospital, Harvard Medical School, Boston, MA (US)
Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is an Associate Professor of Medicine at Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA. Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management.
She also has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda served on the Professional Practice Committee of the American Diabetes Association (Standards of Care in Diabetes 2021, 2022, 2023) and on the international 2022 ADA-EASD Consensus Group for the Management of Hyperglycemia in Type 2 Diabetes.
Ashu Rastogi, MD, DM (Endocrinology), MNAMS, FACE, FRCP (Edin)
Addl. Prof., Department of Endocrinology, PGIMER, Chandigarh, India
Published 140 Research papers in Indexed journalsHony. Secretary, Diabetic Foot Society of India (DFSI).
Hony. Secretary, RSSDI (Chandigarh Chapter).
Executive Committee Member, Endocrine Society of India.
Young Investigator Award, American Association of Clinical Endocrinology, USA 2012.
Best Research Award, IWGDF, Hague, Netherland, 2019.
RSSDI IJDDC Award 2022 for Best Published Research paper.
Shehla Sajid Shaikh, MD, DM (Endocrinology)
Consultant Endocrinologist Saifee Hospital and Reliance Hospital, Mumbai, India
Principal Investigator in International Clinical Trials – 35.
Member of Executive Committee, E.S.I., Diabetes India.
Past Treasurer-ESI, Maharashtra.
Member of Scientific Committee, CAD.
Awarded Top Docs Mumbai by T.O.I. group from 2017-2020.
Author of international Hajj and Diabetes guidance and IDF-DAR guidelines 2021.
Published many papers, review articles and speaker at national and international forums.
Manash P. Baruah, MD, DM(AIIMS),FACE(USA)
Promoter Director, HOD, Department of Endocrinology, Apollo Excelcare Hospitals, Guwahati, India
Co-opted Executive member and joint secretary Endocrine Society of India (2020-21, 2021-22)
National Expert: Certificate Course in Management of Thyroid Disorder (CCMTD) , an initiative of Public Health Foundation of India (PHFI) and Chellaram Diabetes Institute(CDI), Pune (2015-2017) Formerly: Editor in Chief , Journal of Medical Nutrition & Nutraceuticals (JMNN2012-2015), Associate Editor, Indian Journal of Endocrinology & Metabolism (IJEM2012-2020), Associate Editor, Thyroid Research and Practice (TRP 2012-16,2022-current).
Reviewer for multiple National & International journals.
223 publications ( originals, reviews, editorials, abstracts) ; >7,000 CITATIONS,CITATIONS, 25 consensus/clinical guidelines >400 scientific communications (platform/web based) as faculty
Dr. Ganapathi Bantwal, MD, DM (Endocrinology), DNB (Endo), MNAMS
Professor and Head of the Department of Endocrinology at St. John’s Medical College Hospital, Bangalore, India
Dr. Ganapathi Bantwal is a reputed and experienced Endocrinologist practising in Bangalore.
Principal Investigator in more than 80 Clinical Trials and Studies.
Has published several Papers in peer-reviewed, indexed journals, both national and international. (>100).
Vice President-Karnataka endocrine society (22-23); Past President – Endocrine society of India.(2020-21).
Recipient of RSSDI oration award 2014, Nada gouda oration award 2009, Dr Sunilkumar Basu Oration award 2019.
